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a b s t r a c t
Background and objective: There is a high incidence of childhood tuberculosis in
Latvia, including children aged less than 1 year, while BCG-associated lymphadenitis
is one of the most frequent adverse events requiring surgical treatment. The aim of this
study was to analyze the incidence of purulent BCG adenitis through-out the population
of Latvia after the introduction of BCG-SSI® vaccine and to evaluate the treatment
results.
Material and methods: The study included 194 patients. All patients had received the BCG-
SSI® vaccine during the first week of life routinely or at a later time according to the
indications. The indications for surgical treatment were lymph node destruction also
affecting the skin. All patients in this study received surgical treatment – the affected lymph
node extirpation.
Results: The mean age of the patients was 5.12  0.96 months. A total of 172 patients had
purulent axillar lymphadenitis, 14 had purulent supraclavicular lymphadenitis, 8
patients had lymphadenitis at both localizations. During the whole study period the
incidence of BCG adenitis varied from 0.02% to 0.36%, while the mean rate was 0.11%
 0.08% from 184,068 vaccinated children during the study period. We observed an
increasing trend in the incidence of BCG lymphadenitis during the study period. The
primary and complete healing rate at the end of period was 99.5% (n = 193) following an
affected lymph node extirpation. The mean hospitalization time after the operation was
3.71  0.18 days.
Conclusions: The incidence of BCG-SSI® vaccine associated purulent lymphadenitis varied
widely with an increasing trend, followed by the return to the product characteristic limits.
Indications for the surgical treatment should not be changed. Extirpation of the purulent
BCG adenitis is a safe treatment method and leads to the primary wound healing in the
majority of cases.
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Bacillus Calmette–Guerin (BCG) vaccination is a part of the
immunization programs in the countries with a risk of
childhood tuberculosis [1–4]. In different countries there are
different schedules for BCG vaccination, starting from the
maternity home [5] to the 6th year of life [6]. The vaccine was
recommended in Europe in 2005 for children under one year of
age in 12 different countries, for older children in 5 countries,
only at risk groups in 10 countries, and no routine vaccination
in 7 countries [6]. The early BCG vaccination between 2 and 5
days after the birth is a part of the compulsory childhood
immunization program in Latvia, due to the high incidence of
childhood tuberculosis, including the children under one year
of age [7,8].
BCG lymphadenitis is one of the BCG vaccination's adverse
events, related to the Category NR1 – Abnormal BCG primary
complex [9,10]. Its incidence differs depending on the
particular vaccine, the age of the child at the time of
vaccination and probably some other factors [6,9].
The treatment of BCG lymphadenitis is still controversial
[5,11–14]. While indications for the surgical treatment are
rather clear, particular treatment methods are still discussed
and opinions differ among different countries, centers and
authors [5,15–18].
Today there is only one BCG vaccine available in the
European Union – BCG-SSI® vaccine from Staten's Serum
Institute (M Bovis, Danish Strain 1331), which is distributed in
vials, containing 10 doses of 0.1 mL of vaccine for children over
12 months of age and adults, or 20 doses of 0.05 mL for infants
under 12 months. The BCG-SSI® vaccine has been the only one
used in the Republic of Latvia since the year 2005.
The clinical effects and the elevated number of the adverse
reactions of the BCG-SSI® vaccine have been described in a
number of publications. Those about the adverse reactions
give different results, and try to concentrate mostly on the
vaccine-related reasons [5,6,10,19–21]. A sudden increase in
incidence of the purulent BCG adenitis was recognized also in
Latvia in 2010 and 2011. It lead to a tri-lateral discussion among
the State Drug Agency (the Government's Pharmacovigilance
Office), the Statens Serum Institute and the Latvian Associa-
tion of Paediatric Surgeons, followed by the implementation of
the BCG-SSI® vaccine manufacturing changes and an instruc-
tion campaign about the vaccination procedure, performed by
The State Drug Agency in the first part of 2012 [22]. After this
successful campaign we observed a decline in the incidence of
BCG adenitis in the subsequent years.
The aim of this study was to analyze the incidence
dynamics of purulent BCG adenitis through-out the popula-
tion of Latvia after the introduction of BCG-SSI® vaccine and to
evaluate the treatment results.
2. Material and methods
A retrospective study was undertaken and medical records of
194 children, admitted to the only reference center in Latvia for
major BCG vaccination associated adverse events, from the
year 2005 to 2013, were reviewed. The study included patientsfrom 1 to 17 months of age with the diagnosis of histologically
proven purulent BCG lymphadenitis. All patients received the
BCG-SSI® vaccine (M Bovis, Danish strain 1331) on the
ipsilateral arm via an intradermal injection. 163 patients
(84.02%) received the BCG-SSI® vaccine during the first week of
life, while 31 patients (15.98%) received it later due to different
medical or social reasons. Observing the signs and symptoms
of BCG adenitis all patients were consulted by a pediatrician
specializing in child tuberculosis and an immunologist.
Indications for surgical treatment were assessed by a pediatric
surgeon. The indications for surgical treatment were lymph
node destruction with the overlying skin involvement. All
patients in this study received surgical treatment – purulent
lymph node extirpation. All patients were consulted and
operated in one reference center by one pediatrician special-
izing in child tuberculosis, one immunologist and operated by
two pediatric surgeons. All patients had postoperative out-
patient follow-up controls up to 18 months. The incidence of
purulent BCG lymphadenitis of less than 0.1% reported by the
producer in the ‘‘Description of BCG vaccine SSI’’ was
considered as a comparator [23]. The study was approved by
the Institutional Ethics Review Board.
Data were analyzed using descriptive and analytical
statistical methods. Mean values and 95% CI of the age of
the hospitalized patients, time after vaccination, incidence of
purulent BCG adenitis and postoperative time were calculated.
The Mann–Kendall trend test was used to determine possible
trends in the occurrence of purulent BCG lymphadenitis over
the particular time. A P value of less than 0.05 was chosen as
the level of significance.
3. Results
A total of 184,068 children had received the BCG-SSI® vaccine
countrywide during the whole study period, from 17,633 to
23,123 children each year [24]. Of these 615 patients developed
BCG lymphadenitis, while 194 patients aged from 1 to 17
months (the mean age was 5.12  0.96 months) were admitted
for surgical treatment of purulent BCG lymphadenitis. The
main characteristics of the study population and study
findings are presented in Table. All children were healthy
and none had reported close contact with any tuberculosis
patient prior to hospitalization. The number of patients in
each year of the study varied, and the maximum incidence
was observed in the period between 2010 and 2012 with the
peak in 2011 (Table). During the whole study period the
incidence of BCG adenitis varied, while the mean incidence
was 0.11%  0.08% (Figure). A total of 180 patients had purulent
axillar lymphadenitis, from 4 to 59 each study year, 14 patients
had purulent supraclavicular lymphadenitis, from 0 to 6 each
study year. Of the 194 patients, 8 had lymphadenitis at both
localizations.
There was a statistically significantly increasing trend in
the incidence of BCG vaccine associated purulent lymphade-
nitis during the period 2005–2013 (Kendall's tau = 0.667;
P = 0.013), especially in the 3-year span between 2010 and
2012 with the peak incidence in 2011 (0.36%, 95% CI 0.28–0.45,
P = 0.05) that significantly differed from the mean incidence of
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the complete healing rate at the end of period was 99.5%
(n = 193). The mean hospitalization time after the operation
was 3.71  0.18 days.
The re-hospitalization rate was 3.1% (n = 6). Five of these
patients were hospitalized due to the repeated purulent BCG
lymphadenitis in a different localization. One patient had
prolonged lymphorrhea for 14 days and had to undergo
repeated hospitalization and drainage correction for another 3
days. Among the concomitant diseases in our study cohort,
two patients were diagnosed with secondary immunodefi-
ciency, four had thymus hyperplasia; three patients, iron
deficiency anemia; one, asthma; one, atopic dermatitis; one,
undetermined heart disease; and one patient, acute bronchi-
tis. All patients recovered and did not show evidence of
lymphadenitis or systemic tuberculosis after 6–18 months of
follow-up.
4. Discussion
BCG vaccination is recommended routinely for all newborns in
the universal immunization program in countries where the
incidence of tuberculosis infection is more than 1% [3]. Rates of
notified TB among children under 15 years of age in Latvia
have been increasing since 2009: from 14.9 to 19.9 per 100,000
in 2011 [8]. The increasing rate also reflects an increase in the
absolute number of cases: from 40 to 61 [8]. These figures,
obviously, illustrate the necessity to continue the already
confirmed immunization program in countries like Latvia,
which presumes to vaccinate all newborns, in the maternity
home with the only exceptions being in cases where there are
contraindications or where there is a refusal from the parental
side.
The BCG-SSI® vaccine (M Bovis, Danish strain 1331) is the
only BCG vaccine used in Latvia since 2005. A high risk of
complications could lead to the loss of trust in vaccination and
potentially cause a threat for children growing up in country
with high incidence of tuberculosis. In our series the annual
frequency of purulent BCG lymphadenitis varied remarkably
(Figure). Despite the decrease in the birth-rate and therefore
number of newborns vaccinated, there had been a steady
increase in numbers of children with purulent lymphadenitis
diagnosed since 2005–2011, which had been proved statisti-
cally.
The incidence of purulent BCG adenitis had been reported
from 0% to 0.31% by different authors [2,19]. The relevance of
purulent lymphadenitis to BCG vaccination was proved
according to the clinical and histopathological findings
[14,18]. The acceptable incidence of purulent BCG adenitis
had been estimated from 0.04% to 0.1% [6,19]. Factors
influencing the formation of the purulent BCG lymphadenitis
are multiple [1,3,20]. They could be separated from the factors
directly related to the BCG-SSI® vaccine as biological material,
factors related to the indications for surgical treatment and
factors related to the technical difficulties during the proce-
dure [6]. Among the last group of factors we considered
vaccination during the neonatal period, the vaccinators' skills
and experience, the diameter and the tip angle of the needle
and changes in the nursing care education programs and
Figure – Annual incidence of purulent BCG lymphadenitis 2005–2013.
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profile nurses), which is particularly necessary for current
health care of Latvia.
The higher incidence of the local adverse reactions,
including purulent lymphadenitis, associated with BCG-SSI®
vaccine, has been widely discussed, however, the statistical
results are still controversial [1,4–6,10,12,19]. The statistical
analysis of the variable dynamics of our 9-year incidence of
purulent BCG lymphadenitis obviously showed (Figure) that the
true reason for the difference that we had observed could not be
explained by the effect of the biological characteristics of BCG-
SSI® vaccine alone. It could not also be explained by the human
factors alone, related to the indications for surgical treatment,
which had not been changed during the whole study period. All
patients were consulted and operated in one reference center
by one team of specialists. The most difficult group to estimate
was the third group of procedure related factors, which could
definitely contribute more to the increase of the variations in
the incidence of purulent BCG lymphadenitis that we observed.
We tend to an opinion that the incidence of BCG
lymphadenitis is influenced by the biological characteristics
of the BCG-SSI® vaccine and by the difficulties, related in
performing the correct vaccination procedure for all infants in
the country during the early new-born period. We suppose
that the possible proof of that is the positive effect of the
activities taken during the year 2011 and 2012, the implemen-
tation of changes in the manufacture of the BCG-SSI® vaccine
(formulated by the producer as ‘‘manufacturing changes, that
are expected to decrease the frequency of suppurative
lymphadenitis, including severe cases’’) and the vaccination
procedure education program [22], which have led to the
return of the incidence of purulent BCG lymphadenitis to an
admissible level in 2013. The mean incidence during the whole
study period stayed slightly above the incidence reported by
the producer, which could be a result of the increase we had in
the period of 2010–2012.Discussions were started between the State Drug Agency
and the experts from pediatric surgery in the 2nd half of 2010,
but the Statens Serum Institute also got involved in 2011.
These corresponded with the period of the growing incidence
of BCG lymphadenitis in our study. The implementation of the
countrywide vaccination procedure education program
started from the beginning of 2012 and the BCG-SSI® vaccine
manufacturing changes were implemented later the same
year. In 2012 the incidence of BCG lymphadenitis had declined,
and in 2013 it returned to the authorized limits. The
indications and the operating techniques were reviewed, but
left without any changes so far.
Purulent BCG lymphadenitis occurs in both groups of
children, in those vaccinated in the new-born period and in
those, vaccinated later, so we agree with the previous published
opinions [6] that the procedure related difficulties are not
connected so much with the patient's age, rather than with the
vaccinator's professionalism in general. However, it was not
the aim of this particular study, there were hints in our
material, that the patients' age and the present indications for
the surgical treatment had less influence on the incidence of
purulent BCG lymphadenitis, while the vaccination procedure
training, instructions and education program together with
close collaboration with the vaccine producer could improve
the results remarkably. We suppose that the vaccination
schedule and the indications for surgical treatment should
not been changed, but purulent BCG lymphadenitis incidence
control, vaccination procedure education activities and contact
with the vaccine producer could be planned more regularly.
Treatment of BCG related purulent lymphadenitis is still
controversial and there are no specific guidelines in the
European Union for the treatment of BCG induced lymphade-
nitis [11–14,16,17]. Surgical treatment of BCG lymphadenitis is
needed in cases of the formation of a skin lesion and the
fixation in a region of the lymph node or the formation of
fistulae with the spontaneous evacuation of pus. Medical
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nodes have developed the fluctuation and inflammation of
overlying skin [16–18]. Incision and drainage should be avoided
due to the risk of persistent draining wound [1]. In Latvia
indications for surgical treatment are approved by the
pediatric surgeon on the recommendation of the pediatrician
specializing in childhood tuberculosis and of the immunolo-
gist. The mean time of the operation was 3.94  0.85 months
after the vaccination. Two methods of the surgical treatment
of purulent BCG lymphadenitis are accepted in the major
discussions, i.e. the needle aspiration, in many cases com-
bined with the following excision of the purulent lymph node,
or the single one moment excision [1,13,16–19]. Single surgical
procedure prevents further complications and gives reliable
treatment results with primary healing, low recurrence rate
and a relatively short postoperative hospital stay. However,
the necessary attention should be paid to follow the natural
course of BCG lymphadenitis and to control the indications for
the cases referred for surgical treatment.
5. Conclusions
The incidence of BCG-SSI® vaccine associated purulent
lymphadenitis varied widely during the study period with
an increasing trend, followed by the return to the product's
characteristic limits. Indications for the surgical treatment of
purulent BCG lymphadenitis should not be changed. Extirpa-
tion of purulent BCG adenitis, despite its larger scale of
intervention, is a safe treatment method and leads to the
primary wound healing in the majority of cases.
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